Clinical Trial Update: Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating oncolytic MG1-MAGEA3 with Ad-MAGEA3 vaccine in combination with pembrolizumab for non-small cell lung cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ad-MAGEA3 vaccine (Ad-MAGEA3)
• MG1-MAGEA3 (MG1-MAGEA3)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Turnstone Biologics, Corp. | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED